Cobo AC

Idioma: Español
Referencias bibliográficas: 32
Paginas: 128-133
Archivo PDF: 76.46 Kb.

FRAGMENTO

La preocupación por la prevención de las enfermedades cardiovasculares ha ido en aumento, debido a la alta prevalencia de las mismas. El objetivo de este artículo es revisar la literatura en relación a los efectos benéficos del ácido acetilsalicílico (aspirina) y de la vitamina E sobre el corazón.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Katzung G. Antiinflamatorios no esteroides; antirreumáticos modificadores de enfermedad; analgésicos no opioides; antiurémicos. En: Katzung B. Farmacología básica y clínica. México, DF. Manual Moderno 1999: 669-696.

2. Final report on the aspirin component of the on going Physicians Health Study. Steering Committee of Th Phy-sicians´Health Study Research Group. NEJM 1989; 321: 129-135.

3. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001; 85: 265-271.

4. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C et al. Randomized trial of prophylactic dairy aspirin in British male doctors. BMJ 1988; 926: 313-316.

5. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina: a randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114: 835-839.

6. Juul-Möller S, Edvardson N, Jahnmatz B, Rosen A, Sorensen S, Ömblus R, for the Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421-1425.

7. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither. Lancet 1988; 2: 349-360.

8. Roux S, Christeller S, Lüdin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992; 19: 671-677.

9. Awtry E, Loscalzo J. Aspirin. Circulation 2000; 101: 1206.

10. Antiplatelet Trialists´ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.

11. Baim DS, Carroza JP. Stent thrombosis: closing in on the best preventive treatment. Circulation 1997; 95: 1098-1100.

12. Goldman S, Copeland J, Morwitz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988; 77: 1324-1332.

13. Weiss W. Fat-Soluble Vitamins. En: Goodman and Gilman. The Pharmacological Basis of Therapeutics, New York. The MacMillan Company. 1970: 1690-1699.

14. Goth A. Vitaminas. En: Goth A. Farmacología Clínica. México DF. Editorial Interamericana. 1977: 454-462.

15. Wilson J. Vitamin deficiency and excess. En: Harrison´s. Principles of Internal Medicine. New York McGraw-Hill 1998: 480-489.

16. Díaz MN, Frei B, Vita JA. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337: 408-416.

17. Tran T. Antioxidant supplements to prevent heart disease. Real hope or empty hype? Postgrad Med 2001; 109: 1.

18. Spencer A, Stier D, Crouch M. Vitamin E and Coronary Artery Disease. Arch Intern Med 1999; 159: 1313-1320.

19. Emmert DH, Kirchner JT. The role of vitamin E in the prevention of heart disease. Arch Fam Med 1999; 8: 537-542.

20. Rimm E, Stampfer M, Ascherio A, Giovannucci E, Colditz G, Willett W. Vitamin E consumption and the risk of coronary heart disease in men. NEJM 1993; 328: 1450-1456.

21. Stampfer M, Hennekens Ch, Manson J, Colditz G, Rosner B, Willett W. Vitamin E consumption and the risk of coronary heart disease in women. NEJM 1993; 328: 1444-1449.

22. De Lorgeril M, Salen P, Martgin J. Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-785.

23. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-786.

24. Virtamo J, Rapola JM, Ripatti S. Effect of vitamin E and beta carotene on the incidence of primary myocardial infarction and fatal coronary heart disease. Arch Intern Med 1998; 158: 688-675.

25. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E Supplementation and Cardiovascular Events in High Risk Patients. NEJM 2000; 342: 154-160.

26. Sica D. The Heart Outcomes Prevention Evaluation (HOPE) Study: Limitations and Strengths. J Clin Invest 2000; 2: 406-409.

27. Gruppo Italiano per lo Studio della sopravivenza nell´Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-455.

28. Polasek J. Acetylsalicylic acid and vitamin E in prevention of arterial thrombosis. Can J Cardiol 1997; 13: 533-535.

29. Steiner M. Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease. Nutr Rev 1999; 57: 306-309.

30. Byshchewskil AS, Galiyan SL, Vakulin AA, Dement´eva IA, Sabirov AX. Influence of vitamins-antioxidants on antiaggregative effect of acetylsalicylic acid. WMJ 1997; 69: 93-98.

31. Podhaisky HP, Abate A, Polte T, Oberle S, Schroder H. Aspirin protects endothelial cells from oxidative stress-possible synergism with vitamin E. FEBS 1997; 417: 349-351.

32. Pryor WA. Vitamin E and heart disease: Basic science to clinical intervention trials. Free Radic Biol Med 2000; 28: 141-164.